A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. METHODS. Metastatic RCC patients were treated with temozolomide, 200 mg/m(2) per day orally, and traditional radiologic response endpoints were assessed. O(6)-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.